Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 67c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($3.21), $0.67 better than the analyst estimate of ($3.88). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $5.18 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Lowe's slashes full-year sales outlook amid DIY spending pressure
• Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance